This schematic illustration shows the major organs that are affected by and contribute to the development of pancreatic cancer cachexia. With pancreatic cancer at the center of the crosstalk network, ...

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

Cross-talk between macrophages and tumor cells could modulate cachexia in pancreatic cancer patients. A group of scientists from the University of Oklahoma has discovered a new pathway that promoted ...

Researchers at the University of Houston are pushing the boundaries of biomedical innovation with a discovery that could transform treatment for one of cancer's most devastating complications. In a ...

CHICAGO – A multimodal, artificial intelligence (AI)-driven model that analyzes routinely collected imaging and clinical information led to more accurate prediction of cancer cachexia than standard ...

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation ...